ArticleBMC women's health2025
Exploring Nectin-4 as a potential diagnostic biomarker in endometrial adenocarcinoma : Title page.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study explored Nectin-4 expression in endometrial adenocarcinoma and examined its relationship with tumor grade, hormone receptor status, p53 expression, and mismatch repair (MMR) protein expression.
methodsWe retrospectively analyzed 55 paraffin-embedded tissue samples collected between 2015 and 2023, including endometrial adenocarcinoma, endometrial intraepithelial neoplasia (EIN), and normal endometrium samples. Nectin-4 expression was assessed via immunohistochemistry, and correlations with clinicopathological features and molecular markers were evaluated statistically.
resultsNectin-4 expression increased with histological grade (p < 0.001). All Grade III tumors presented strong expression, whereas lower-grade tumors presented variable staining. The expression of these genes was also correlated with p53 overexpression (p = 0.007) and PMS2 loss (p = 0.002). Nectin-4 was absent in normal tissues and weakly expressed in EIN.
conclusionNectin-4 expression is linked to high-grade endometrial carcinoma and abnormal p53 expression, supporting its potential role as a diagnostic biomarker. Larger studies are needed to validate its clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.